An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer

Watch this Webcast and download the slides from a CCO symposium at ASCO 2019 to get up to date on how experts are managing patients with HR-positive HER2-negative MBC in the context of an evolving treatment paradigm.

Share

Program Content

Activities

CDK4/6i for HR+/HER2- MBC
CDK4/6 Inhibitors in the Management of HR+/HER2- MBC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2019

Expires: May 29, 2020

PI3K Blockade in HR+/HER2- MBC
Targeting the PI3K Pathway in HR+/HER2- MBC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2019

Expires: May 29, 2020

Future Directions in HR+/HER2- MBC
Promising Strategies on the Horizon for HR+/HER2- MBC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2019

Expires: May 29, 2020

Activities

Treatment of HR+/HER2- MBC
An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: July 05, 2019

Expires: July 04, 2020

Faculty

cover img faculity

Adam M. Brufsky, MD, PhD

Associate Professor
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Supporters

This activity is supported by independent educational grants from

Lilly

Novartis Pharmaceuticals Corporation